Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

ABSTRACT:

Background

No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.

Methods

In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic urothelial carcinoma either to receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to six cycles, followed by nivolumab (at a dose of 480 mg) every 4 weeks for a maximum of 2 years, or to receive gemcitabine-cisplatin alone every 3 weeks for up to six cycles. The primary outcomes were overall and progression-free survival. The objective response and safety were exploratory outcomes.

Results</

SUBMITTER: van der Heijden MS 

PROVIDER: S-EPMC12314471 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature